X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs GLENMARK PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS GLENMARK PHARMA IPCA LABS/
GLENMARK PHARMA
 
P/E (TTM) x 27.5 13.6 201.4% View Chart
P/BV x 2.1 3.8 55.1% View Chart
Dividend Yield % 0.2 0.3 73.4%  

Financials

 IPCA LABS   GLENMARK PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
GLENMARK PHARMA
Mar-16
IPCA LABS/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs6431,262 51.0%   
Low Rs503672 74.9%   
Sales per share (Unadj.) Rs254.4270.6 94.0%  
Earnings per share (Unadj.) Rs16.124.9 64.6%  
Cash flow per share (Unadj.) Rs29.834.4 86.5%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.2 84.4%  
Book value per share (Unadj.) Rs194.6151.3 128.6%  
Shares outstanding (eoy) m126.20282.16 44.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.6 63.0%   
Avg P/E ratio x35.738.9 91.7%  
P/CF ratio (eoy) x19.228.1 68.5%  
Price / Book Value ratio x2.96.4 46.1%  
Dividend payout %6.28.0 77.4%   
Avg Mkt Cap Rs m72,300272,778 26.5%   
No. of employees `00013.310.0 132.7%   
Total wages/salary Rs m6,96013,782 50.5%   
Avg. sales/employee Rs Th2,413.57,614.9 31.7%   
Avg. wages/employee Rs Th523.21,374.8 38.1%   
Avg. net profit/employee Rs Th152.4700.2 21.8%   
INCOME DATA
Net Sales Rs m32,10676,340 42.1%  
Other income Rs m226356 63.4%   
Total revenues Rs m32,33276,696 42.2%   
Gross profit Rs m4,44814,172 31.4%  
Depreciation Rs m1,7302,691 64.3%   
Interest Rs m2411,789 13.5%   
Profit before tax Rs m2,70310,048 26.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6753,028 22.3%   
Profit after tax Rs m2,0287,019 28.9%  
Gross profit margin %13.918.6 74.6%  
Effective tax rate %25.030.1 82.9%   
Net profit margin %6.39.2 68.7%  
BALANCE SHEET DATA
Current assets Rs m17,34059,096 29.3%   
Current liabilities Rs m9,55940,018 23.9%   
Net working cap to sales %24.225.0 97.0%  
Current ratio x1.81.5 122.8%  
Inventory Days Days10075 133.8%  
Debtors Days Days57119 47.7%  
Net fixed assets Rs m20,77939,075 53.2%   
Share capital Rs m252282 89.4%   
"Free" reserves Rs m24,49930,281 80.9%   
Net worth Rs m24,55342,703 57.5%   
Long term debt Rs m3,51724,873 14.1%   
Total assets Rs m39,595111,026 35.7%  
Interest coverage x12.26.6 184.8%   
Debt to equity ratio x0.10.6 24.6%  
Sales to assets ratio x0.80.7 117.9%   
Return on assets %5.77.9 72.2%  
Return on equity %8.316.4 50.3%  
Return on capital %10.517.5 59.9%  
Exports to sales %48.643.3 112.4%   
Imports to sales %14.27.4 191.6%   
Exports (fob) Rs m15,61733,044 47.3%   
Imports (cif) Rs m4,5715,672 80.6%   
Fx inflow Rs m15,61736,945 42.3%   
Fx outflow Rs m5,82861,066 9.5%   
Net fx Rs m9,790-24,122 -40.6%   
CASH FLOW
From Operations Rs m2,7643,449 80.2%  
From Investments Rs m-1,432-8,802 16.3%  
From Financial Activity Rs m-1,5916,986 -22.8%  
Net Cashflow Rs m-259934 -27.7%  

Share Holding

Indian Promoters % 45.9 48.3 95.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 6.9 165.2%  
FIIs % 25.3 34.4 73.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 10.5 165.7%  
Shareholders   36,892 56,727 65.0%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  UNICHEM LAB  MERCK LTD  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 22, 2017 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - GLENMARK PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS